Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients

ConclusionsThese results raise the question whether axillary node status is redundant in cases with exceptionally good features, i.e., small tumors with low Ki67, or in those candidate to adjuvant systemic treatment/radiotherapy anyway including TNBC, and support the incorporation of primary BC tumor characteristics as stratification factors in ongoing trials aiming at de-escalating axillary surgical procedures.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   HER2-positive Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Trastuzumab emtansine Sponsor:   University of Rochester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionTCHL was a tolerable regimen at a starting L dose of 750  mg PO daily when given concurrently with chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusions: Our report is the first study to examine the distant metastatic breast cancer proteome using FFPE tissues. The depth of our dataset allowed us to discover a novel biomarker candidate and a proteomic characteristics of distant metastatic breast cancer. Distinct molecular features of various breast cancer subtypes were also established. Our proteomic data constitute a valuable resource for research on distant metastatic breast cancer. PMID: 32489334 [PubMed]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Proteomics Source Type: research
Conclusions: In the present study, the most recent and largest administrative database analysis of a Canadian population to date, we observed a subtype distribution consistent with previously reported data, together with comparable annual incidence and overall survival patterns. PMID: 32489268 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
In conclusion, we designed specific and sensitive methods to detect LALBA transcripts. We show for the first time a differential expression of these transcripts, but we need to confirm their potential use as markers in breast cancer. PMID: 32464003 [PubMed - indexed for MEDLINE]
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Authors: Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S Abstract The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the expression of cel...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
British Journal of Cancer, Published online: 03 June 2020; doi:10.1038/s41416-020-0909-4Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
HER2 is a transmembrane tyrosine kinase receptor, belonging to the epidermal growth factor receptor (EGFR) family, which is overexpressed in less than 20% of breast cancers [1]; as early as 1986, HER2 was established as a strong negative prognostic marker [2]. The monoclonal antibody trastuzumab was the first targeted agent specifically designed for the treatment of HER2-positive BC. Trastuzumab is directed against the extracellular domain of HER2 leading to the inhibition of the receptor, and blockade of the autophosphorylation cascade, and cell degradation via immunological effects.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Italy Health